Antibody Engineering and Design
|Event Date/Time: Feb 23, 2010||End Date/Time: Feb 25, 2010|
Because it's been designed by you.
It's been designed by people from companies like Genentech, MedImmune, Roche, Abbott, Johnson & Johnson, Biogen Idec, Merck, UCB Celltech, Pfizer and many other big pharmaceutical companies and innovative biotechs.
Shorn of tired case studies and company overviews, the focus is on delivering practical value to your antibody drug development activities.
Covering challenges and opportunities identified by you, you'll leave this meeting with a raft of new ideas and contacts to take back to your organization.
Hear speakers talk about overcoming problems you're facing with a level of frankness and sincerity you can't get from any other antibody event.
Meet innovative scientists and research leaders from big pharma and large biotech, and understand how they meet the challenges associated with engineering and designing more effective antibody drugs.
What's on the agenda?
Here are just some of topics covered on the agenda:
Engineering antibodies with enhanced characteristics. Isotype choice, half life, stability, efficacy, immunogenicity, using structural insights and moreâ€¦
Utilizing structural-based drug design. How to enhance structural understanding, epitope mapping and using crystallization studies to improve subsequent development
Reduction of manufacturing risk and improving expression early in the development process
How to ensure appropriate species cross-reactivity
How to improve anti-tumour activity through better antibody design. The thoughts of several of the world's leading oncology experts and case studies
Generation of multivalent antibodies and use combinatorial strategies to combat cancer
Discovery of suitable antibody candidates and identification new targets via novel strategies